In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report). The company’s shares opened today at $1.70.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inmune Bio, and Indaptus Therapeutics. According to TipRanks, McCarthy has an average return of -15.0% and a 30.41% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $20.00 average price target.
RVPH market cap is currently $47.74M and has a P/E ratio of -1.07.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Reviva Pharmaceuticals Holdings (RVPH) Company Description:
Tenzing Acquisition Corp. is a blank check company, which engages in the acquisition of similar business combination with one or more businesses and entities. It focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction. The company was founded on March 20, 2018 and is headquartered in New York, NY.
Read More on RVPH:
- Reviva Pharmaceuticals Progresses with Global Schizophrenia Trial
- Reviva announces enrollment update for OLE study on brilaroxazine
- Reviva Pharmaceuticals Operational Performance Insights
- Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Reviva Pharmaceuticals reports Q1 EPS (25c), consensus (38c)
